Memo Therapeutics Stock

Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.

Sign up today and learn more about Memo Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Memo Therapeutics Stock

Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis. Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’s immune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery. MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.

Funding History

July 2015$2.3M
May 2018$5.0M
November 2020$14.0M
December 2021$10.5M
February 2022$23.0M
November 2023$25.0M

Management

Member of the board

Michael Sidler

Board of Director

Christian Schneider

Founder & CEO

Christoph Esslinger

Board of Director

Philippe Dro

Board of Director

Andreas Wüpper

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo